Cardinal Health, Inc.

Good day and welcome to first quarter fiscal year 2023 Cardinal Health earnings conference call. Today's call is being recorded. I will now hand the call over to Kevin Moran, Vice President of Investor Relations. Please go ahead, sir.

Good morning and welcome. Today we will discuss Cardinal Health first quarter fiscal 2023 results, along with updates to our full year outlook. You can find today's press release and earnings presentation on the IR section of our website at ir.cardinalhealth.com. Joining me today are Jason Holler, Chief Executive Officer, and Trish English, Interim Chief Financial Officer. During the call, we will be making forward-looking statements. The matters addressed in the statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected or implied. Please refer to our SEC filing and the forward-looking statement slide at the beginning of our presentation for a full description of these risks and uncertainties. Please note that during the discussion today, our comments will be on a non-GAAP basis unless they are specifically called out as GAAP. GAAP to non-GAAP reconciliation for all relevant periods can be found in the schedules attached to our press release. During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so that we can try and give everyone in the queue an opportunity. With that, I'll now turn the call over to Jason.

Thanks, Kevin, and good morning, everyone. Now that I've had a couple months to settle into the CEO role, I'm feeling even more energized and excited about the opportunities in front of us. My recent conversations with customers, suppliers, employees, and shareholders have reinforced my perceptions that, Our company's role in healthcare and our mission to improve the lives of people every day remain as critical as ever. Our customers and their patients rely on us to deliver the right products to the right places at the right time. And yet, there's also a collective recognition of the need for simplification, focused execution, and clarification of our company's strategic direction. Our goal today, along with reviewing our recent results, is to summarize the key near-term priorities and progress to date on our plans. which I will discuss later in my remarks. However, before I turn it over to Trish, let me share some initial perspective on the first quarter. Overall, our performance in the first quarter demonstrated continued stable fundamentals in our largest business and tangible progress in medical. In pharma, we track slightly ahead of our expectations as we deliver growth while managing industry-wide inflationary headwinds. We are encouraged by the ongoing stability in prescription volumes and strong performance of our generics program. In medical, quarter's results were also a little better than expectations we announced in September. While I'm pleased with our team's efforts in the quarter to achieve these results, there is more work to be done to drive better, more predictable financial performance in line with the underlying potential of this business. We are highly focused on executing our medical improvement plan initiatives, which I will cover in greater detail later in my remarks. Across the company, our team is operating with urgency to drive our businesses forward and committed to creating value for our shareholders. Now, I'll turn it over to Trish to dive deeper into our results and outlook.